During the last session, X4 Pharmaceuticals Inc (NASDAQ:XFOR)’s traded shares were 1.17 million, with the beta value of the company hitting 0.09. The 52-week high for the XFOR share is $1.60, that puts it down -226.53 from that peak though still a striking 46.94% gain since the share price plummeted to a 52-week low of $0.26. The company’s market capitalization is $83.21M, and the average intraday trading volume over the past 10 days was 3.08 million shares, and the average trade volume was 3.75 million shares over the past three months.
X4 Pharmaceuticals Inc (XFOR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. XFOR has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) trade information
X4 Pharmaceuticals Inc (XFOR) registered a -0.29% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.29% in intraday trading to $0.49, hitting a weekly high. The stock’s 5-day price performance is 7.04%, and it has moved by -23.90% in 30 days. Based on these gigs, the overall price performance for the year is -35.07%. The short interest in X4 Pharmaceuticals Inc (NASDAQ:XFOR) is 11.42 million shares and it means that shorts have 8.64 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 83.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $5 respectively. As a result, XFOR is trading at a discount of -920.41% off the target high and -512.24% off the low.
X4 Pharmaceuticals Inc (XFOR) estimates and forecasts
Statistics show that X4 Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. X4 Pharmaceuticals Inc (XFOR) shares have gone down -38.78% during the last six months, with a year-to-date growth rate more than the industry average at 71.93% against 16.50.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.06M as predicted by 6 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 2.53M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 73.95%. While earnings are projected to return 77.19% in 2025.
XFOR Dividends
X4 Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
X4 Pharmaceuticals Inc (NASDAQ:XFOR)’s Major holders
X4 Pharmaceuticals Inc insiders own 1.15% of total outstanding shares while institutional holders control 67.66%, with the float percentage being 68.45%. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the largest shareholder of the company, while 126.0 institutions own stock in it. As of 2024-06-30, the company held over 16.92 million shares (or 8.4582% of all shares), a total value of $9.81 million in shares.
The next largest institutional holding, with 14.99 million shares, is of NEA MANAGEMENT COMPANY, LLC’s that is approximately 7.4937% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $8.69 million.
Also, the Mutual Funds coming in first place with the largest holdings of X4 Pharmaceuticals Inc (XFOR) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 5.03 shares. This amounts to just over 2.95 percent of the company’s overall shares, with a $2.46 million market value. The same data shows that the other fund manager holds slightly less at 4.2, or about 2.46% of the stock, which is worth about $2.05 million.
